{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:21:12Z","timestamp":1776496872187,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2334-14-474","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T11:01:23Z","timestamp":1409569283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety of poly-L-lactic acid (New-Fill\u00ae) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Martin","family":"Duracinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Odile","family":"Christen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Dolivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Goujard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Chassany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"3780_CR1","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Ghisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet. 1999, 353: 2093-2099. 10.1016\/S0140-6736(98)08468-2.","journal-title":"Lancet"},{"issue":"5","key":"3780_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1089\/aid.2012.0214","volume":"29","author":"P Leclercq","year":"2013","unstructured":"Leclercq P, Goujard C, Duracinsky M, Allaert F, L\u2019Henaff M, Hellet M, Meunier JP, Carret S, Thevenon J, Van Ngo P, Pialoux G: High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy. AIDS Res Hum Retroviruses. 2013, 29 (5): 761-768. 10.1089\/aid.2012.0214.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"3780_CR3","volume-title":"Prise en charge des personnes infect\u00e9es par le VIH","author":"P Yeni","year":"2010","unstructured":"Yeni P: Prise en charge des personnes infect\u00e9es par le VIH. 2010, Paris: M\u00e9decine-Sciences Flammarion"},{"issue":"3","key":"3780_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00002018-200124030-00001","volume":"24","author":"E Martinez","year":"2001","unstructured":"Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM: Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 2001, 24 (3): 157-166. 10.2165\/00002018-200124030-00001.","journal-title":"Drug Saf"},{"issue":"7","key":"3780_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/apc.2007.0173","volume":"22","author":"G Guaraldi","year":"2008","unstructured":"Guaraldi G, Murri R, Orlando G, Giovanardi C, Squillace N, Vandelli M, Beghetto B, Nardini G, De Paola M, Esposito R, Wu AW: Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008, 22 (7): 577-585. 10.1089\/apc.2007.0173.","journal-title":"AIDS Patient Care STDS"},{"issue":"18","key":"3780_CR6","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"S Duran","year":"2001","unstructured":"Duran S, Sav\u00e8s M, Spire B, Cailleton V, Sobel A, Carrieri P, Moatti JP, Leport C, APROCO Study Group: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001, 15 (18): 2441-2444. 10.1097\/00002030-200112070-00012.","journal-title":"AIDS"},{"key":"3780_CR7","volume-title":"Prise en charge des personnes vivant avec le VIH - Recommandations du groupe d\u2019experts","author":"P Morlat","year":"2013","unstructured":"Morlat P: Prise en charge des personnes vivant avec le VIH - Recommandations du groupe d\u2019experts. 2013, Paris: CNS ANRS Rapport"},{"issue":"9","key":"3780_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1089\/apc.2008.0230","volume":"23","author":"LP Sturm","year":"2009","unstructured":"Sturm LP, Cooter RD, Mutimer KL, Graham JC, Maddern GJ: A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. Aids Patient Care STDS. 2009, 23 (9): 699-714. 10.1089\/apc.2008.0230.","journal-title":"Aids Patient Care STDS"},{"issue":"7","key":"3780_CR9","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1097\/00002030-200311210-00009","volume":"17","author":"MA Valantin","year":"2003","unstructured":"Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Castigliola D, Katlama C: Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003, 17 (7): 2471-2477.","journal-title":"AIDS"},{"key":"3780_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2334-13-92","volume":"13","author":"M Duracinsky","year":"2013","unstructured":"Duracinsky M, Leclercq P, Armstrong AR, Dolivo M, Mouly F, Chassany O: A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use. BMC Infect Dis. 2013, 13: 92-99. 10.1186\/1471-2334-13-92.","journal-title":"BMC Infect Dis"},{"key":"3780_CR11","unstructured":"Commission d\u2019Evaluation des Produits et Prestations: Avis de la Commission. Dispositif: NEW-FILL, acide L-polylactique (updated 25 September 2012). http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2013-01\/new_fill-25_septembre_2012_4321_avis.pdf (accessed on 26 August 2014)"},{"key":"3780_CR12","unstructured":"World Medical Association: Declaration of Helsinki - Ethical principles for medical research involving human subjects. [ http:\/\/www.wma.net\/en\/30publications\/"},{"key":"3780_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/biomet\/35.3-4.246","volume":"35","author":"FJ Anscombe","year":"1958","unstructured":"Anscombe FJ: The transformation of Poisson, binomial and negative binomial data. Biometrika. 1958, 35: 246-254.","journal-title":"Biometrika"},{"issue":"2","key":"3780_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaad.2004.08.056","volume":"52","author":"CM Burgess","year":"2005","unstructured":"Burgess CM, Quiroga RM: Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol. 2005, 52 (2): 233-239. 10.1016\/j.jaad.2004.08.056.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3780_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/QAI.0b013e318158bec9","volume":"46","author":"DL Carey","year":"2007","unstructured":"Carey DL, Backer D, Rogers GD, Petoumenos K, Chuan J, Easey N, Machon K, Cooper DA, Emery S, Carr A: Facial LipoAtrophy Study in HIV Investigators: A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune Defic. 2007, 46 (5): 581-589. 10.1097\/QAI.0b013e318158bec9.","journal-title":"J Acquir Immune Defic"},{"issue":"3","key":"3780_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/archderm.142.3.329","volume":"142","author":"AM Cattelan","year":"2006","unstructured":"Cattelan AM, Bauer U, Trevenzoli M, Sasset L, Campostrini S, Facchin C: Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol. 2006, 142 (3): 329-334.","journal-title":"Arch Dermatol"},{"issue":"6","key":"3780_CR17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350501000606","volume":"10","author":"G Guaraldi","year":"2005","unstructured":"Guaraldi G, Orlando G, De Fazio D, De Lorenzi I, Rottino A, De Santis G, Pedone A, Spaggiari A, Baccarani A, Borghi V, Esposito R: Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther. 2005, 10 (6): 753-759.","journal-title":"Antivir Ther"},{"issue":"4","key":"3780_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/01.qai.0000152834.02912.98","volume":"38","author":"M Lafaurie","year":"2005","unstructured":"Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM: Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005, 38 (4): 393-398. 10.1097\/01.qai.0000152834.02912.98.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"3780_CR19","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaad.2008.07.027","volume":"59","author":"RM Levy","year":"2008","unstructured":"Levy RM, Redbord KP, Hanke CW: Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol. 2008, 59 (6): 923-933. 10.1016\/j.jaad.2008.07.027.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"3780_CR20","first-page":"1336","volume":"32","author":"DR Mest","year":"2006","unstructured":"Mest DR, Humble G: Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg. 2006, 32 (11): 1336-1345.","journal-title":"Dermatol Surg"},{"issue":"3","key":"3780_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1468-1293.2006.00342.x","volume":"7","author":"GJ Moyle","year":"2006","unstructured":"Moyle GJ, Brown S, Lysakova L, Barton SE: Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006, 7 (3): 181-185. 10.1111\/j.1468-1293.2006.00342.x.","journal-title":"HIV Med"},{"issue":"12","key":"3780_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/apc.2006.20.829","volume":"20","author":"E Negredo","year":"2006","unstructured":"Negredo E, Higueras C, Adell X, Martinez JC, Martinez E, Puig J, Fumaz CR, Munoz-Moreno JA, Perez-Alvarez N, Videla S, Estany C, Cinquegrana D, Gonzales-Mestre V, Clotet B: Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances. AIDS patients Care STDs. 2006, 20 (12): 829-837. 10.1089\/apc.2006.20.829.","journal-title":"AIDS patients Care STDs"},{"issue":"12","key":"3780_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.bjps.2008.07.046","volume":"62","author":"J Ong","year":"2009","unstructured":"Ong J, Clarke A, White P, Johnson MA, Withey S, Butler PE: Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment. J Plast Reconstr Aesthet Surg. 2009, 62 (12): 1627-1635. 10.1016\/j.bjps.2008.07.046.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"11","key":"3780_CR24","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1089\/apc.2007.0029","volume":"21","author":"G Orlando","year":"2007","unstructured":"Orlando G, Guaraldi G, De Fazio D, Rottino A, Grisotti A, Blini M, De Santis G, Pedone A, Spaggiari A, Baccarani A, Vandelli M, De Paola M, Comelli D, Nardini G, Beghetto B, Squillace N, Esposito R: Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, non-randomized study. AIDS Patient Care STDS. 2007, 21 (11): 833-842. 10.1089\/apc.2007.0029.","journal-title":"AIDS Patient Care STDS"},{"issue":"6","key":"3780_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.stomax.2007.04.005","volume":"108","author":"M Piquet","year":"2007","unstructured":"Piquet M, Brignol L, Chatelain B, Rey D, Ricbourg B, Meyer C: Polylactic acid injections: usefulness for the treatment of facial lipoatrophy in HIV\u2009+\u2009patients under tritherapy. Rev Stomatol Chir Maxillofac. 2007, 108 (6): 496-504. 10.1016\/j.stomax.2007.04.005.","journal-title":"Rev Stomatol Chir Maxillofac"},{"key":"3780_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1473-2165.2009.00417.x","volume":"8","author":"F Rossner","year":"2009","unstructured":"Rossner F, Rossner M, Hartmann V, Erdmann R, Wiest LG, Rzany B: Decrease of reported adverse events to injectable polylactic acid after recommending an increased dilution: 8\u00a0years results from the Injectable Filler Safety Study. J Cosmet Dermatol. 2009, 8: 14-18. 10.1111\/j.1473-2165.2009.00417.x.","journal-title":"J Cosmet Dermatol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-14-474\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-14-474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T01:55:09Z","timestamp":1650074109000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-14-474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3780"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-14-474","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]},"assertion":[{"value":"12 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"474"}}